The lack of target therapies is accountable for the higher mortality of various types of cancer. To address this issue, we selected a target mutated Kirsten rat sarcoma virus oncogene homologue, which plays a significant role in various cancers. Our study aims to identify selective biomarkers and develop diagnostic and therapeutic strategies for KRAS-associated genes using artificial intelligence. Initially, Genomic data, cancer epidemiology, proteomics network interactions, and omics enrichment were analyzed. Structured E-pharmacophore model aided in capturing the binding cavity using eraser algorithms and fabricating a new selective lead compound for the KRSA. The selective molecule was abridged inside the binding cavity and stability was validated through 100 ns molecular dynamics simulations. Epidemiological-neural network studies indicated KRAS mutations leads 40 types of cancer, exclusively pancreatic and colorectal cancers, with diploid and missense mutations as primary factors. Pathway analysis highlighted the involvement of the MAPK and RAS signaling pathways in cancer development and proteomics analysis identified RALGDS as a key protein. Protein-based pharmacophore analysis mapped the biologically active features such as donor, acceptor and aromatic ring with the designed ligands. The results of interaction interpretation illustrate that the amino acid Tyr566 formed an H-bond interaction with the amine group of the octyl ring system and 20 amino acids crafted to properly orient the molecule to fit inside the polar cavity of KRAS protein. The MMGBSA score of − 53.33 kcal/mol conformed to the well-configured binding with KRSA and realistic model simulation exposed the π–π, π–cationic and hydrophobic interactions stabilised the molecule inside the KRSA protein throughout 100 ns simulation. The study demonstrates the vitality of AI and network pharmacology to identify potential-target biomarkers for KRAS-associated genes, paving the way for improved cancer diagnostics and therapeutics.
20 November 2025 in Journal of Drug Delivery Science and Technology
This study depicts the selected dose of Allium sativum (104 mg/kg body weight) on the hypoglycemic activity of preferred dose of gliclazide which are studied in normal wistar rats. Materials required for the study are procured from Sai Chemicals, Visakhapatnam, India. Mature wistar rats of both the sex were used for the study. Prior to the trial the rats were confined for 18 hr with access to water ad libitum. During the study water was removed. Orally gliclazide was administered at 0.5 mg/kg, 1 mg/kg, 2 mg/kg body weight to I, II and III groups respectively. Blood samples are taken by retro-orbital puncture at intervals of 0, 1, 2, 3, 4, 6, 8, 10, 12 & 16 hr and blood glucose levels were determined by GOD/POD method. The acute dose of Allium sativum when given along with gliclazide increased the hypoglycemic activity of gliclazide at 2nd, 6th and 8th hr intervals but it was significant at 2nd hr only and the effect was shown to be reduced at all other ie., 1st, 3rd, 10th and 12th hr time intervals. The aqueous extract of Allium sativum is influencing the absorption pattern of gliclazide since it was reported to have an increasing motility of the gastro intestinal tract.
The physicochemical properties of the physiological makeup and the chemical componentof the system make this challenging throughout strenuous procedure. The current review concentrated on in silico modelling of drug disposition, involving absorption process, distribution process, and excretion process and includes thorough knowledge of various database expeditions, the development of a pharmacophore model, molecular docking studies, homology modelling supported sequence similarity and quantitative structure-activity relationships (QSAR)/ quantitative structure-property relationships (QSPR) evaluation along with all information about drug movement and related computational tools for understanding potential chemical and pathophysiological changes. The primary development in ADMET modeling in current times has been the clarification of the function and effective modeling of various transporters. In ADMET modelling, there is still work to be done on including the impact of these transporters into existing models. The present state of modelling different elements of drug disposal at the systemic level will then be discussed, along with recent developments in modelling a wide range of active transporters and their effects on drug pharmacokinetic profiles. A more thorough knowledge of the underlying processes governing different aspects of drug disposition should also lead to an increase in mechanism-based modelling methods that are simple to grasp and put into practice. These developments will hasten the transition of model construction from computational to experimental scientists.